Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

	Dec '19	Dec '20	Dec '21
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	2.42M -	3.18M 31.29%	10.26M 223.14%
selling general and administrative expenses	2.42M -	3.18M 31.29%	10.26M 223.14%
research and development expenses	8.24M -	14.90M 80.84%	32.26M 116.57%
other expenses
cost and expenses	10.66M -	18.07M 69.59%	42.52M 135.30%
operating expenses	10.66M -	18.07M 69.59%	42.52M 135.30%
interest expense	38K -	48K 26.32%	314K 554.17%
ebitda	-10.86M -	-17.78M 63.67%	-41.99M 136.15%
operating income	-10.66M -	-18.07M 69.59%	-41.99M 132.38%
depreciation and amortization	-208K -	1K 100.48%	6K 500%
total other income expenses net	-246K -	242K 198.37%	-314K 229.75%
income before tax	-10.90M -	-17.83M 63.55%	-42.31M 137.29%
income tax expense		3K -	2K 33.33%
net income	-10.90M -	-17.83M 63.58%	-42.31M 137.26%
weighted average shs out	13.38M -	13.38M 0%	13.38M 0%
weighted average shs out dil	13.38M -	13.38M 0%	13.38M 0%
eps	-0.81 -	-1.33 64.20%	-3.16 137.59%
epsdiluted	-0.81 -	-1.33 64.20%	-3.16 137.59%

COM:IMAGOBIO

Imago BioSciences, Inc.

Last Close

36.01

10/01 21:00

Volume Today

138.13K

Avg: -

Preview